ABBV Earnings Preview: AbbVie Q2 2026 on April 29

By Danny Kontos

April 28, 2026

6 min read

Share with:

preferred News SourceSelectMeykaasyourpreferredNewsSource

Key Points

AbbVie expects $2.62 EPS and $14.72B revenue on April 29

Company beat estimates in three of last four quarters

Key watch: HUMIRA, SKYRIZI sales and forward guidance

B+ grade reflects solid fundamentals but elevated valuation metrics

AbbVie Inc. (ABBV) will report second-quarter 2026 earnings on April 29 after market close. Analysts expect earnings per share of $2.62 and revenue of $14.72 billion. The pharmaceutical giant has consistently beaten earnings estimates over the past four quarters, raising investor expectations for another strong performance. With a market cap of $349.1 billion and a Meyka AI grade of B+, ABBV remains a key player in the healthcare sector. Understanding what to watch during this earnings report is crucial for investors monitoring the company’s momentum.

Earnings Estimates and Analyst Expectations

Analysts project solid results for AbbVie’s Q2 2026 earnings report. The consensus EPS estimate stands at $2.62, while revenue expectations reach $14.72 billion. These figures reflect steady demand for the company’s pharmaceutical portfolio.

EPS Forecast Analysis

The $2.62 EPS estimate represents a modest decline from the previous quarter’s $2.71 actual result. However, it remains above the Q3 2025 estimate of $1.77, showing overall strength. This estimate suggests AbbVie’s earnings power remains resilient despite market headwinds and competitive pressures in the pharmaceutical industry.

Revenue Expectations

The $14.72 billion revenue estimate falls below the prior quarter’s $16.62 billion actual result. This decline reflects typical seasonal patterns in pharmaceutical sales. The estimate still demonstrates year-over-year growth momentum, supporting analyst confidence in AbbVie’s core business fundamentals and product portfolio performance.

Historical Beat and Miss Pattern

AbbVie has demonstrated a strong track record of beating analyst expectations over recent quarters. This consistent outperformance suggests management’s ability to execute and potentially exceed current guidance.

Recent Quarter Performance

In the most recent quarter (Q1 2026), AbbVie reported EPS of $2.71 versus an estimate of $2.65, beating by $0.06. Revenue came in at $16.62 billion against an estimate of $16.41 billion. The previous quarter showed similar strength with EPS of $1.86 versus $1.77 expected. This pattern of consistent beats indicates strong operational execution and effective cost management.

Implications for Q2 Results

Based on this four-quarter beat pattern, investors should monitor whether AbbVie maintains its outperformance streak. The company’s ability to exceed expectations on both EPS and revenue metrics has become a defining characteristic. If this trend continues, the stock could see positive momentum following the earnings announcement.

Key Metrics and What to Watch

Several important metrics will shape investor sentiment following AbbVie’s earnings report. Understanding these factors helps contextualize the company’s financial health and growth trajectory.

Pharmaceutical Portfolio Performance

Investors should closely monitor sales trends for key drugs including HUMIRA, SKYRIZI, and RINVOQ. These products represent significant revenue drivers for the company. Any acceleration or deceleration in these franchises will directly impact future guidance and market expectations for AbbVie’s growth prospects.

Cash Flow and Dividend Sustainability

AbbVie’s free cash flow per share stands at $10.50, supporting the company’s substantial dividend yield of 3.41%. The payout ratio of 2.76 indicates strong dividend coverage. Investors should watch for any commentary on cash generation trends and capital allocation priorities, particularly regarding shareholder returns and research investments.

Guidance and Forward Outlook

Management’s forward guidance will be critical for determining market reaction. Any changes to full-year EPS or revenue expectations could signal confidence or caution about market conditions. Investors should pay attention to commentary on patent cliffs, competitive dynamics, and pipeline progress for future growth drivers.

Meyka AI Grade and Investment Context

Meyka AI rates ABBV with a grade of B+, reflecting a balanced assessment of the company’s financial position and market outlook. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

What the B+ Grade Means

The B+ rating indicates AbbVie is performing solidly relative to peers and broader market benchmarks. The company demonstrates consistent earnings power and strong cash generation. However, the grade suggests room for improvement in certain areas, such as valuation metrics and growth acceleration compared to industry leaders.

Current Valuation Context

AbbVie trades at a PE ratio of 83.63, which appears elevated relative to historical norms. The price-to-sales ratio of 5.72 also reflects premium valuation. Despite these metrics, the company’s dividend yield and cash flow generation provide income-focused investors with attractive characteristics. The stock’s recent decline of 13.6% year-to-date presents a potential entry point for value-oriented investors.

Final Thoughts

AbbVie’s Q2 2026 earnings report on April 29 will test whether the company can maintain its impressive beat streak. With analyst expectations of $2.62 EPS and $14.72 billion revenue, investors should focus on pharmaceutical portfolio performance, cash flow trends, and forward guidance. The company’s consistent outperformance over recent quarters, combined with its B+ Meyka AI grade, suggests solid operational execution. However, elevated valuation metrics warrant careful attention to management commentary on growth drivers and competitive positioning. The earnings report will provide critical insight into whether AbbVie can sustain momentum in an increasingly competitive healthcare landscape.

FAQs

What are analysts expecting from AbbVie’s Q2 2026 earnings?

Analysts project EPS of $2.62 and revenue of $14.72 billion, reflecting steady pharmaceutical demand and consistent operational performance from AbbVie’s core business.

Has AbbVie beaten earnings estimates recently?

Yes, AbbVie beat EPS estimates in three of the last four quarters, most recently reporting $2.71 versus $2.65 expected, demonstrating strong execution and consistent outperformance.

What should investors watch during the earnings call?

Monitor HUMIRA and SKYRIZI sales trends, cash flow generation, dividend sustainability, management guidance, and commentary on patent cliffs and pipeline progress.

What does the B+ Meyka AI grade mean for AbbVie?

The B+ grade indicates solid performance versus S&P 500 benchmarks and sector peers, reflecting strong cash generation and earnings power with limited upside at current valuations.

Is AbbVie’s dividend safe after earnings?

Yes, the dividend is safe. Free cash flow per share of $10.50 and a 2.76 payout ratio provide strong coverage, supporting AbbVie’s mature cash generation profile.

Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.